Nan Jia

Nan Jia is a Senior Manager in Biostatistics specializing in Oncology Late Phase Development at AstraZeneca. They previously held roles as a Research Scientist at Eli Lilly and Company, where they served as the safety lead for the NDA submission of Lasmiditan, and as a Senior Manager at Sanofi, leading late phase development for Immuno-Oncology compounds. Nan also worked as a Graduate Student Research Assistant at the University of Michigan and a Senior Scientist at Merck & Co, Inc. They earned a Doctor of Philosophy (Ph.D.) in Biostatistics from the University of Michigan School of Public Health.